Sangamo Therapeutics (SGMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 176,232 | 111,299 | 110,701 | 118,192 | 102,428 |
| Gross Profit | 176,232 | 111,299 | 110,701 | 118,192 | 102,428 |
| Operating Expenses | 450,237 | 312,580 | 294,038 | 247,744 | 207,608 |
| Operating Income | -274,005 | -201,281 | -183,337 | -129,552 | -105,180 |
| Other Income | 11,102 | 9,432 | 5,346 | 8,775 | 9,761 |
| Pre-tax Income | -262,903 | -191,849 | -177,991 | -120,777 | -95,419 |
| Income Tax | -5,072 | 429 | 306 | 345 | N/A |
| Net Income Continuous | -257,831 | -192,278 | -178,297 | -121,122 | -95,419 |
| Minority Interests | N/A | N/A | -11 | -126 | -233 |
| Net Income | $-257,831 | $-192,278 | $-178,286 | $-120,996 | $-95,186 |
| EPS Basic Total Ops | -1.48 | -1.25 | -1.23 | -0.90 | -0.85 |
| EPS Basic Continuous Ops | -1.48 | -1.25 | -1.23 | -0.90 | -0.85 |
| EPS Diluted Total Ops | -1.48 | -1.25 | -1.23 | -0.90 | -0.85 |
| EPS Diluted Continuous Ops | -1.48 | -1.25 | -1.23 | -0.90 | -0.85 |
| EPS Diluted Before Non-Recurring Items | -0.59 | -1.25 | -1.23 | -0.90 | -0.85 |
| EBITDA(a) | $-164,657 | $-181,961 | $-162,855 | $-117,008 | $-100,281 |